深夜，暴雷！刚刚，直线大跳水！欧洲巨头，崩了

Core Viewpoint - The European weight loss drug giant Novo Nordisk has faced significant stock sell-offs following its earnings report, which projected a larger-than-expected decline in sales and operating profit for 2026, leading to a sharp drop in its stock price [1][4]. Group 1: Stock Performance and Market Reaction - Novo Nordisk's stock price fell over 5% in the U.S. market and nearly 20% in European trading, significantly impacting the OMXC20 index, which dropped over 6% [2][3]. - The company's stock has seen a cumulative decline of nearly 49% in 2025, marking it as the worst-performing year in its history [5]. Group 2: Financial Forecasts - For 2025, Novo Nordisk expects sales to grow by 6% to 309.06 billion Danish Krone, slightly above analyst expectations, with a net profit increase of 1.4% to 102.43 billion Danish Krone [3]. - The company anticipates a decline in sales and operating profit for 2026, projecting a decrease of 5% to 13%, which is significantly worse than the expected decline of 1.4% [4]. Group 3: Market Dynamics and Analyst Predictions - Analysts have downgraded global weight loss drug market growth forecasts, with Goldman Sachs predicting a market size of $105 billion by 2030, down from a previous estimate of $130 billion, due to increased pricing pressure and changing consumer usage patterns [1][7]. - The competitive landscape is shifting, with new drugs entering the market and generic competition increasing, prompting a reassessment of market peak size and timing [7][8].